81
Participants
Start Date
March 31, 2014
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2015
10% reduction of combination of Esmeron® and Nimbex®
Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
20% reduction of combination of Esmeron® and Nimbex®
The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
Yonsei University
OTHER